a phase i/ii study of a 72-h continuous infusion of etoposide in advanced soft tissue sarcoma
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

a phase i/ii study of a 72-h continuous infusion of etoposide in advanced soft tissue sarcoma

;Charles R. Crawley;Ian R. Judson;Mark Verrill;Catherine Hill;Florence I. Raynaud
the journal of physiology 1997 Vol. 1 pp. 149-154
192
crawley1997sarcomaa

Abstract

Purpose. The study was performed to assess the antitumour activity and toxicity of a 72-h continuous infusion of single-agent etoposide as second-line treatment for patients with locally advanced or metastatic soft tissue sarcoma (STS), following reports of substantial activity using this schedule of etoposide administration as first-line treatment in combination with ifosfamide.

Keywords

neoplasms Oncology including cancer and carcinogens tumors

Access

DOI:
10.1080/13577149778236
URL:
http://dx.doi.org/10.1080/13577149778236

Citation

ID: 185123
Ref Key: crawley1997sarcomaa
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
185123
Unique Identifier:
10.1080/13577149778236
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store